This point was already addressed by others who demonstrated that downregulation of DNMT3A and DNMT3B led to regulation of ESR1 or ESR2 via promoter DNA aberrant methylation in acute myeloid leukemia, endometriosis, prostate and ovarian cancer [49]–[52]. This evidence concerns the gene DNMT3A and ovarian carcinoma.